CD274 and neoplasm: Patients who are more likely to respond to CAR-T cells may also be identified by biomarkers that indicate an immune-supportive tumor microenvironment, such as increased PD-L1 expression or decreased levels of immunosuppressive cells (like Tregs or MDSCs), particularly when used in conjunction with immune checkpoint inhibitors.